Teva Pharmaceutical Industries (TEVA) Cash from Operations: 2009-2025
Historic Cash from Operations for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Sep 2025 value amounting to $369.0 million.
- Teva Pharmaceutical Industries' Cash from Operations fell 46.75% to $369.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 billion, marking a year-over-year decrease of 42.56%. This contributed to the annual value of $1.2 billion for FY2024, which is 8.85% down from last year.
- Per Teva Pharmaceutical Industries' latest filing, its Cash from Operations stood at $369.0 million for Q3 2025, which was up 62.56% from $227.0 million recorded in Q2 2025.
- Teva Pharmaceutical Industries' 5-year Cash from Operations high stood at $1.2 billion for Q4 2023, and its period low was -$405.0 million during Q1 2021.
- Its 3-year average for Cash from Operations is $282.4 million, with a median of $227.0 million in 2025.
- Per our database at Business Quant, Teva Pharmaceutical Industries' Cash from Operations plummeted by 232.79% in 2021 and then spiked by 13,760.00% in 2024.
- Teva Pharmaceutical Industries' Cash from Operations (Quarterly) stood at $456.0 million in 2021, then surged by 113.38% to $973.0 million in 2022, then increased by 21.69% to $1.2 billion in 2023, then slumped by 51.44% to $575.0 million in 2024, then tumbled by 46.75% to $369.0 million in 2025.
- Its last three reported values are $369.0 million in Q3 2025, $227.0 million for Q2 2025, and -$105.0 million during Q1 2025.